
microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

CEPI commits up to US$80m to University of Oxford to develop vaccines
The US$80m strategic partnership of CEPI, which was established in 2016 in the wake of the Ebola virus outbreak in west Africa, the University of...

Antiverse and GlobalBio Inc. extend collaboration
AI specialist Antiverse Ltd (Cardiff, UK) and antobody engeeniering expert GlobalBio, Inc. (New York, USA) will be extending their collaboration to...

Alfasigma SpA set to take over Galapagos programme
Under the planned agreement, Alfasigma SpA will pay €50m upfront, milestones totaling €120m and mid-single to mid-double digit royalties on European...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

Pierre Fabre Laboratories collaborate with Vernalis
The French biotech company combines its experience in innovation, development, manufacturing, and commercialisation in oncology with the expertise of...

Recordbreaking BIO-Europe in Munich, but: back to 2019
Record figures and a much better mood in Europe than one is currently hearing from the USA. Financing is difficult at the moment and the US...